Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
O., et al
Last Published 05.01.2026 Effective Date: 02.01.2026 This policy addresses minimally invasive procedures for the treatment of upper gastrointestinal diseases
/assets/images/provider/photos/2803587.png)
Saxenda a higher-dose daily liraglutide formulation Wegovy a higher-dose weekly semaglutide formulation Zepbound the weight-loss formulation of tirzepatide These medications are typically approved for adults with obesity, or for those who are overweight with additional health conditions such as high blood pressure, abnormal cholesterol, or sleep apnoea
Semaglutide treatment predicted greater reductions in heavy drinking over time compared to placebo 22
US$ 26.87
US$ 25.44
US$ 24.51
US$ 21.63
US$ 20.64
